ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing

Abstract Summary We introduce shallowHRD, a software tool to evaluate tumor homologous recombination deficiency (HRD) based on whole genome sequencing (WGS) at low coverage (shallow WGS or sWGS; ∼1X coverage). The tool, based on mining copy number alterations profile, implements a fast and straightforward procedure that shows 87.5% sensitivity and 90.5% specificity for HRD detection. shallowHRD could be instrumental in predicting response to poly(ADP-ribose) polymerase inhibitors, to which HRD tumors are selectively sensitive. shallowHRD displays efficiency comparable to most state-of-art approaches, is cost-effective, generates low-storable outputs and is also suitable for fixed-formalin paraffin embedded tissues. Availability and implementation shallowHRD R script and documentation are available at https://github.com/aeeckhou/shallowHRD. Supplementary information Supplementary data are available at Bioinformatics online.

[1]  Z. Szallasi,et al.  Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer , 2018, npj Breast Cancer.

[2]  Isidro Cortés-Ciriano,et al.  Detecting the mutational signature of homologous recombination deficiency in clinical samples , 2019, Nature Genetics.

[3]  P. Gestraud,et al.  Histo‐genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non‐BRCAness high grade ovarian carcinoma , 2015, International journal of cancer.

[4]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[5]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[6]  L. Saal,et al.  Whole-genome-sequencing of triple negative breast cancers in a population-based clinical study , 2019, Nature Medicine.

[7]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[8]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[9]  Tom Sante,et al.  Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients , 2017, Clinical Cancer Research.

[10]  Nikhil Wagle,et al.  Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors , 2017, Nature Communications.

[11]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[12]  A. Sethi,et al.  The Cancer Genomics Cloud: Collaborative, Reproducible, and Democratized-A New Paradigm in Large-Scale Computational Research. , 2017, Cancer research.

[13]  M. Morgan,et al.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. , 2019, The New England journal of medicine.

[14]  Tatiana Popova,et al.  Supplementary Methods , 2012, Acta Neuropsychiatrica.

[15]  E. Barillot,et al.  Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays , 2009, Genome Biology.

[16]  Z. Szallasi,et al.  Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.

[17]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..